![]() |
市场调查报告书
商品编码
1776214
旋切术设备:市场洞察·竞争情形·市场预测 (~2032年)Atherectomy Devices - Market Insights, Competitive Landscape, and Market Forecast - 2032 |
预计到2032年,动脉粥状硬化斑块切除器械市场将保持稳定的复合年增长率,这主要得益于心血管疾病和生活方式相关疾病患病率的上升、认知度和筛检项目的加强,以及全球主要公司产品开发活动的增加。
预计动脉粥状硬化斑块切除器械市场规模将从2024年的10.4594亿美元增长到2032年的20.8337亿美元,预测期内的复合年增长率为9.05%。
心血管疾病和生活型态相关疾病(例如糖尿病和肥胖症)盛行率的上升,推动了用于治疗动脉粥状硬化的动脉粥状硬化斑块切除器械的需求。此外,认知度的提高和筛检计画的推进,使得动脉阻塞的早期发现和诊断成为可能,从而增加了对动脉粥状硬化斑块切除干预措施的需求。此外,主要厂商在动脉粥状硬化斑块切除技术方面的进步正在提高精准度和安全性,使这些设备能够更有效地治疗复杂病例。这些因素正在刺激全球动脉粥状硬化斑块切除设备市场的成长。总体而言,预计在2025年至2032年的预测期内,这些因素将推动动脉粥状硬化斑块切除设备市场的发展。
动脉粥状硬化斑块切除设备市场动态:
根据英国心臟基金会2025年的数据,全球约有6.4亿人(约占全球人口的1/12)患有心臟和循环系统疾病。
此外,根据基金会2024年的数据,冠心病(缺血性心臟病)是全球最常见的疾病,估计影响着2亿人,其中包括约1.1亿男性和8000万女性。此外,据报道,约有5600万女性和4500万男性在中风后倖存下来。据估计,至少有1300万人患有先天性心臟病,还有数百万人可能未被诊断。心血管疾病 (CVD) 通常会导致动脉粥状硬化,即动脉中积聚斑块,导致动脉狭窄或阻塞,因此对有效治疗的需求日益增长。动脉粥状硬化切除器械可以去除斑块并恢復血流,使其成为治疗冠状动脉疾病和周边动脉疾病的重要组成部分。因此,动脉粥状硬化被认为是心肌梗塞、中风、週边动脉疾病和心臟病发作的主要原因。治疗动脉粥状硬化对于预防这些严重的心血管疾病至关重要,这使得动脉粥状硬化切除器械的使用日益普及。因此,心血管疾病盛行率的上升预计将推动对动脉粥状硬化切除器械的需求,从而在预测期内促进市场成长。
推动动脉粥状硬化斑块切除术设备市场成长的另一个关键因素是对微创设备和手术的需求不断增长。这是因为微创方法的优势得到了广泛认可,例如与传统外科手术相比,其癒合速度更快、对身体的创伤更小。动脉粥状硬化斑块切除术设备(例如定向动脉粥状硬化斑块切除术)被视为一种无需使用支架等植入装置即可切除阻塞性内膜增厚和动脉粥样硬化病变的微创治疗方法。此外,动脉粥状硬化斑块切除术也有助于避免外科手术相关的瘢痕和发炎等副作用。预计这些优势将在未来进一步推动动脉粥状硬化斑块切除术设备市场的成长。
各大公司的策略性举措和技术创新也促进了市场的全球扩张。预计这些因素将在预测期内推动全球市场的成长。
本报告研究了全球动脉粥状硬化斑块切除设备市场,提供了市场概况、市场影响因素和市场机会分析、监管环境、市场规模趋势和预测、按细分市场、地区和主要国家/地区进行的详细分析、竞争格局以及主要公司的概况。
Atherectomy Devices Market by Product Type (Directional, Rotational, Photoablative, and Orbital), End-User (Hospitals, Specialty Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the rising prevalence of cardiovascular diseases, increase in prevalence of lifestyle disorders, rising awareness and screening programs, and increase in product development activities by key market players across the globe.
The atherectomy devices market was valued at USD 1,045.94 million in 2024, growing at a CAGR of 9.05% during the forecast period from 2025 to 2032, to reach USD 2,083.37 million by 2032. The rising prevalence of cardiovascular diseases and lifestyle disorders, such as diabetes and obesity, is driving the demand for atherectomy devices to treat atherosclerosis. Additionally, growing awareness and screening programs have led to earlier detection and diagnosis of arterial blockages, resulting in higher demand for atherectomy interventions. Furthermore, the advancements in atherectomy technology by key market players are improving precision and safety, making these devices more effective in treating complex cases. Together, these factors are fueling the growth of the global atherectomy device market. Collectively, these factors are expected to boost the market for atherectomy devices during the forecast period from 2025 to 2032.
Atherectomy Devices Market Dynamics:
According to recent data provided by the British Heart Foundation (2025), globally, approximately 640 million people, or about 1 in 12 individuals, live with heart and circulatory diseases.
Furthermore, as per the recent data provided by the British Heart Foundation (2024), coronary (ischemic) heart disease, the most commonly diagnosed worldwide, affected an estimated 200 million people globally of which 110 million men and 80 million women were affected. Additionally, around 56 million women and 45 million men were stroke survivors. It was estimated that at least 13 million people worldwide lived with congenital heart disease, with potentially millions more undiagnosed. As CVD often leads to conditions like atherosclerosis, where plaque buildup narrows or blocks arteries, the need for effective treatments is rising. Atherectomy devices, which remove plaque and restore blood flow, are becoming essential in managing conditions such as coronary artery disease and peripheral artery disease. Thus, atherosclerosis is considered a major cause of myocardial infarctions, strokes, peripheral arterial disease, and heart attack. To avoid the progression to other serious CVDS, treatment of atherosclerosis becomes imperative wherein the application of atherectomy devices has become a norm. Therefore, the increase in the prevalence of cardiovascular diseases is projected to result in the growing demand for atherectomy devices, thereby contributing to the growth of the atherectomy devices market during the forecast period.
Moreover, another key factor that is aiding in the growth of atherectomy devices is the growing demand for minimally invasive devices and procedures. This can be attributed to the realization of advantages associated with minimally invasive approaches such as faster healing time and significantly less trauma compared to conventional techniques. Atherectomy devices such as directional atherectomy are considered to be a minimally invasive treatment and have been reported to provide a distinct advantage in the removal of obstructive intima hyperplastic or atherosclerotic lesions without the involvement of implantable devices such as stents. Furthermore, atherectomy devices help in avoiding disadvantages associated with surgical procedures such as surgical scarring and inflammation after stent implantation. Therefore, the advantages offered by atherectomy systems are expected to further drive the growth of atherectomy devices during the forecast period.
Moreover, the ongoing strategic activities among the key market players and technological advancement are further boosting the overall market of atherectomy devices across the globe. For instance, in September 2024, AngioDynamics, Inc., a leading medical technology company, announced that it had received European CE Mark approval for its Auryon Atherectomy System, an innovative device for treating Peripheral Artery Disease (PAD), including Critical Limb Ischemia (CLI) and In-Stent Restenosis (ISR).
Therefore, the factors mentioned above are expected to boost the overall market of atherectomy devices across the globe during the forecast period.
However, the atherectomy procedures can lead to complications such as vessel perforation, embolization, or dissection and stringent regulatory concerns for product approvals may hinder the future market of atherectomy devices market growth.
Atherectomy Devices Market Segment Analysis:
Atherectomy Devices Market by Product Type (Directional, Rotational, Photoablative, and Orbital), End-User (Hospitals, Specialty Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the product type segment of the atherectomy devices market, the orbital category is expected to hold the largest share in the year 2024. Orbital atherectomy devices are significantly boosting the overall market of atherectomy devices due to their unique advantages in treating complex cardiovascular conditions, particularly heavily calcified plaques. These devices use an orbiting mechanism to sand down calcified plaque while maintaining the integrity of the arterial walls, making them highly effective for patients with advanced atherosclerosis. Unlike traditional atherectomy devices, which may struggle with calcified lesions, orbital atherectomy systems provide more precise plaque removal, reducing the risk of arterial damage and allowing for improved blood flow. The ability to handle both peripheral artery disease (PAD) and coronary artery disease (CAD) makes orbital devices versatile and increases their demand across various cardiovascular applications.
Additionally, the technology behind orbital atherectomy allows for minimally invasive procedures, which have gained traction due to shorter recovery times, fewer complications, and less pain for patients. As healthcare providers increasingly seek out safer, more efficient treatment methods, orbital atherectomy systems are becoming a preferred option, driving their adoption in hospitals and clinics worldwide. Furthermore, continuous advancements in device design and operational safety have led to higher procedural success rates, which further enhances their reputation in the market.
Additionally, the increase in strategic activities by the key market players is also boosting the overall market of orbital atherectomy devices across the globe. For instance, in October 2023, Cardio Flow, Inc., a privately held medical device company specializing in minimally invasive devices to treat peripheral artery disease (PAD), announced that it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its FreedomFlow orbital atherectomy peripheral platform.
Hence, all the above-mentioned factors are expected to generate considerable revenue for the segment pushing the overall growth of the global atherectomy devices market during the forecast period.
North America is expected to dominate the overall atherectomy devices market:
Among all regions, North America is projected to hold the largest share of the global atherectomy devices market in 2024. Several key factors are driving this growth, including the rising prevalence of cardiovascular diseases such as coronary heart disease and peripheral arterial disease, along with increasing rates of obesity, hypertension, and diabetes. Additionally, the growing elderly population and rising government initiatives focused on disease awareness and treatment are contributing to the market expansion across the region.
As per the recent data from the Centers for Disease Control and Prevention (CDC, 2024), approximately 4.9% of U.S. adults were diagnosed with coronary heart disease in 2022. Moreover, by 2023, an estimated 12.1 million Americans were projected to have atrial fibrillation (AF). Each year, over 795,000 people in the U.S. suffer a stroke, with around 610,000 of these being first-time occurrences. Notably, nearly 185,000 strokes about one in four occur in individuals who have previously had a stroke.
The increasing incidence of AF and strokes significantly contributes to the demand for atherectomy devices. AF elevates the risk of blood clot formation, which can lead to atherosclerosis and subsequent stroke conditions requiring the removal of arterial plaque to restore proper blood flow. Atherectomy devices play a critical role in treating these vascular complications by removing blockages, particularly in AF patients who are more prone to such conditions.
Diabetes is another major contributor to the rising demand for atherectomy devices. Elevated blood glucose levels in diabetic patients can accelerate plaque buildup in the arteries, resulting in narrowing or blockages. According to the CDC (2024), an estimated 38.4 million people in the U.S. 11.6% of the total population had diabetes, with 38 million of them aged 18 and older (14.7% of U.S. adults). If left untreated, diabetes can reduce blood flow to the lower extremities and increase the risk of ulcers, infections, and even amputations. Atherectomy devices are vital in restoring proper circulation by clearing arterial blockages in diabetic patients, thereby supporting market growth.
In addition, extensive product development activities in North America, especially in the United States, are further driving market demand. For instance, in October 2023, Cardio Flow, Inc. announced it had received FDA 510(k) clearance for its FreedomFlow(TM) Orbital Atherectomy Peripheral Platform, designed to treat peripheral artery disease (PAD).
In summary, the combination of high disease burden, a large at-risk population, supportive government initiatives, and technological advancements is expected to significantly boost the North American atherectomy devices market during the forecast period.
Atherectomy Devices Market Key Players:
Some of the key market players operating in the atherectomy devices market include Koninklijke Philips N.V., Medtronic PLC, Boston Scientific Corporation, AngioDynamics Inc., Cardiovascular Systems Inc., Avinger, BD, Ra Medical Systems, REX Medical, Cardio Flow, Inc., and others.
Recent Developmental Activities in the Atherectomy Devices Market:
Key takeaways from the atherectomy devices market report study:
Target audience who can benefit from this atherectomy devices market report study:
Frequently Asked Questions for the Atherectomy Devices Market: